Replimune announces that a brand new abstract from the primary analysis of the IGNYTE clinical trial has been selected for oral presentation at the European Society for Medical Oncology (ESMO) 2024 Congress

22.08.2024 – 08:00 a.m.

WOBURN, Mass., Aug. 22, 2024 (GLOBE NEWSWIRE) — Replimune Group, Inc. (NASDAQ: REPL), a clinical-stage biotechnology company pioneering a new class of oncolytic immunotherapies, today announced that a late-breaking abstract containing the primary analysis from the IGNYTE clinical trial has been selected for an oral presentation at the 2024 European Society for Medical Oncology (ESMO) Congress, to be held in Barcelona, ​​September 13-17, 2024.

Presentation details:

Title: Primary efficacy, safety and survival data from the enrollment cohort of patients with melanoma who have failed anti-PD-1 treatments from the IGNYTE clinical trial of RP1 in combination with nivolumab
Title of the presentation session: Mini Oral Session – Melanoma and other skin tumors
Presentation number: LBA46
Date and time: Sunday, 15 September 2024, 15:45 – 15:50 CEST
Speakers: Caroline Robert, MD, PhD, Gustave Roussy Cancer Center

About RP1
RP1 (vusolimogene or parepvec) is Replimune's lead product candidate and is based on a proprietary strain of herpes simplex virus that has been genetically modified and encoded with a fusogenic protein (GALV-GP R^–) and GM-CSF, which are designed to maximize the tumoricidal effect, the immunogenicity of tumor cell death and the activation of a systemic anti-tumor immune response.

About Replimune
Replimune Group, Inc., headquartered in Woburn, MA, was founded in 2015 with the goal of revolutionizing cancer treatment by developing a novel portfolio of oncolytic immunotherapies. Replimune's proprietary RPx platform is based on a potent HSV-1 backbone designed to maximize immunogenic cell death and induction of a systemic anti-tumor immune response. The RPx platform is designed to have a unique dual local and systemic activity consisting of direct, selective virus-mediated tumor killing resulting in the release of tumor-related antigens and alteration of the tumor microenvironment to elicit a potent and durable systemic response. The RPx product candidates are expected to act synergistically with most established and experimental cancer treatment modalities, resulting in versatility that allows them to be developed alone or in combination with a variety of other treatment options. For more information, visit www.replimune.com.

Forward-looking statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements regarding the design and advancement of our clinical trials, the timing and adequacy of the results of our clinical trials to support potential approval of our product candidates, our goals for developing and commercializing our product candidates, patient enrollment in our existing and planned clinical trials and the timing thereof, and other statements identified by words such as “may,” “expects,” “intends,” “may,” “plans,” “potential,” “should,” “will,” “would” or similar expressions and the negative of these terms. Forward-looking statements are not promises or guarantees of future performance and are subject to a number of risks and uncertainties, many of which are beyond our control and which could cause actual results to differ materially from those anticipated in such forward-looking statements. These factors include risks related to our limited operating history, our ability to achieve positive clinical trial results for our product candidates, the cost and timing of operating our in-house manufacturing facility, the timing and scope of regulatory approvals, the availability of combination therapies required to conduct our clinical trials, changes in laws and regulations to which we are subject, competitive pressures, our ability to identify additional product candidates, political and global macro factors, including the impact of the coronavirus as a global pandemic and related public health issues and the political and military conflicts between Russia and Ukraine and between Israel and Hamas, and other risks that may be detailed from time to time in our Annual Reports on Form 10-K and Quarterly Reports on Form 10-Q and other reports we file with the Securities and Exchange Commission. Our actual results may differ materially from those described or implied by such forward-looking statements. Forward-looking statements speak only as of the date they are made, and except as required by law, we undertake no obligation to update or revise these forward-looking statements.

Inquiries from investors
Chris Brinzey
ICR Westwick
339.970.2843
[email protected]

Media inquiries
Arleen Goldenberg
Replimune
917.548.1582
[email protected]